zinc finger protein 830Genealiases: CCDC16 · OMCG1
Q-omics provides the consensus-scored ZNF830 profile across patient tissues and cancer cell-line models. ZNF830 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF830 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF830 protein abundance shows 23,417 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where ZNF830 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF830 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF830 survival associations across molecular data types. ZNF830 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF830 RNA expression–survival associations across cancer types. High ZNF830 expression shows unfavorable associations in ACC, LIHC, KIRP and UVM, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF830 RNA expression.
This table summarizes ZNF830 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF830. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF830 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, KIRP, HNSC and STAD. The THCA box plot shows higher ZNF830 RNA expression in normal versus tumor tissue (log2 FC = −0.537, t-test p < 0.001).
This table shows molecular features associated with ZNF830 in patient tissues and cancer cell lines. In patient samples, ZNF830 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF830 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
